Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Gliosarcoma × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia, Myeloid, Acute 3 Primary Myelofibrosis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Anemia, Refractory, with Excess of Blasts 2 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Hemoglobinuria, Paroxysmal 1 Hematologic Neoplasms 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Aplastic 1

Interventions

Temozolomide 120 Radiotherapy 81 Bevacizumab 39 Radiation 30 Carmustine 25 Irinotecan 21 Erlotinib Hydrochloride 20 Magnetic Resonance Spectroscopy 19 Chemotherapy, Adjuvant 17 Surgical Procedures, Operative 13 Carboplatin 13 sargramostim 12 O(6)-benzylguanine 12 Radiotherapy, Intensity-Modulated 10 Radiotherapy, Conformal 10 Thalidomide 8 Imatinib Mesylate 8 Drug Therapy 8 Radiosurgery 7 Procarbazine 7 Gene Expression Profiling 7 pembrolizumab 6 motexafin gadolinium 6 cediranib 6 Vorinostat 6 Lomustine 6 Immunohistochemistry 6 Gefitinib 6 Filgrastim 6 Everolimus 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡